Skip to main content
Obizur reconstitution video
For Healthcare Professionals
Instruction video on reconstitution of Obizur
Back to top
Risk Minimisation Materials
Search by company, common medicine name, or title of Risk Minimisation Material
Obizur
Takeda UK Ltd
For Healthcare Professionals
OBIZUR▼[antihaemophilic Factor VIII (recombinant), porcine sequence] HCP Brochure
For Healthcare Professionals
Information On Dose Calculation for OBIZUR▼[antihaemophilic Factor VIII (recombinant), porcine sequence]
Olumiant
Eli Lilly and Company Limited
Olumiant 2 mg and 4 mg Film-Coated Tablets Patient Alert Card
Olumiant 2 mg and 4 mg Film-Coated Tablets Patient Alert Card containing important safety information for patients.
Olumiant 2 mg and 4 mg Film-Coated Tablets guidance for Healthcare Professionals for Atopic Dermatitis and Alopecia Areata
For Healthcare Professionals
Important Risk Minimization information for healthcare professionals prescribing Olumiant for the treatment of Atopic Dermatitis and Alopecia Areata.
Olumiant 2 mg and 4 mg Film-Coated Tablets guidance for Healthcare Professionals for Rheumatoid Arthritis
For Healthcare Professionals
Important Risk Minimization information for healthcare professionals prescribing Olumiant for the treatment of Rheumatoid Arthritis.
Onpattro
Alnylam UK Ltd
Onpattro (patisiran) Educational Material for Healthcare Professionals
For Healthcare Professionals
Educational Material for Healthcare Professionals to ensure safe use of Onpattro in the home setting.
Onpattro (patisiran) Educational Material for Patients
Educational Material for patients for safe use of Onpattro in the home.
OPDIVO
Bristol Myers Squibb Pharmaceuticals limited
Opdivo (nivolumab) Patient Alert Card
The provision of this card to patients is required by the terms of the Marketing Authorisation. Please ensure that you carry this card with you at all times and that you have read and understood this information as it contains important safety information that you need to be aware of before, during and after treatment with nivolumab or nivolumab in combination with ipilimumab. This card was updated in September 2022 (administrative updates only). Changes to the card include design/editorial updates and addition of the Northern Ireland emc url.
Opdualag
Bristol Myers Squibb Pharmaceuticals limited
UK Opdualag (nivolumab and relatlimab) Patient Card
This card is part of the marketing authorisation for Opdualag (nivolumab and relatlimab) and contains important safety information that you need to be aware of. Please also ensure that you carry this card with you at all times to inform any healthcare professional treating you (e.g., emergency department personnel) that you are receiving treatment with nivolumab and relatlimab.
Opfolda
Amicus Therapeutics UK Ltd
POMBILITI (CIPAGLUCOSIDASE ALFA) + OPFOLDA (MIGLUSTAT) INFORMATION PACK FOR HEALTHCARE PROFESSIONALS
INFORMATION PACK FOR HEALTHCARE PROFESSIONALS
Opsumit
Janssen-Cilag Ltd
Opsumit Patient Alert Card
For Healthcare Professionals
It is important that you report immediately to your prescribing doctor any pregnancy or side effects that may occur during treatment with Opsumit.
Orphacol
Laboratoires CTRS
Educational material for healthcare professionals
For Healthcare Professionals
This material for gastroenterologist/hepatologists aims to: Provide correct diagnosis and therapeutic managements of these two deficiencies; Inform on expected and potential risks associated with the treatment, especially prescription of a supratherapeutic dose and gallstones.
Ozurdex
AbbVie Ltd
Ozurdex - Patient Guide
For Healthcare Professionals
A patient guide to OZURDEX therapy Ref: UK-OZU-220475 DOP: Feb 2023
You are trying to reach document intended for healthcare professionals only.
Are you a healthcare professional?
You are trying to reach document intended for healthcare professionals only.
Are you a healthcare professional?
